Apatinib Mesylate (AM; Hengrui Pharmaceutical Co. Ltd, Jiangsu, People’s Republic of China), a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2 or kinase insert domain receptor, KDR), is developed and manufactured in China4, which can selectively inhibit VEGFR-mediated endothelial cell migration and proliferation, thus blocking new blood vessel formation in tumor tissue5. This evidence concerns the gene KDR and neoplasm.